Diabetes mellitus in Kabuki syndrome 1 on a background of post-transplant diabetes mellitus.
Journal article
Chew Sue Mei S. et al, (2024), Endocrinology, diabetes & metabolism case reports, 2024, 23 - 133
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Journal article
Cardoso P. et al, (2024), Diabetologia
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2023), J Diabetes
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Timing of SGLT2i initiation after acute myocardial infarction.
Journal article
von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Journal article
Taylor R. et al, (2023), Clin Sci (Lond)
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Journal article
Regan JA. et al, (2023), JCI Insight
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Journal article
Maddaloni E. et al, (2023), Diabetes Metab Res Rev
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
Teplizumab approval for type 1 diabetes in the USA.
Journal article
Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2023), Diabetes Obes Metab
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Journal article
Maddaloni E. et al, (2023), Diabetes, Obesity and Metabolism
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Journal article
Green JB. et al, (2023), Diabetes, Obesity and Metabolism
What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward
Journal article
Kc S. et al, (2023), International Journal of Health Policy and Management, 12
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Journal article
Shields BM. et al, (2022), Nat Med
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Journal article
Shields BM. et al, (2022), Nat Med
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.
Journal article
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842